Charles River Earnings: Headwinds From Reduced Client Spending; Positive Long-Term Outlook

Narrow-moat Charles River Laboratories continues to experience pressure from cautious client spending amid macroeconomic challenges. A softer demand environment for preclinical testing is particularly weighing on the firm's discovery and safety assessment business as many biopharmaceutical clients have announced restructuring and pipeline reprioritization initiatives. Despite near-term challenges, we think demand trends will stabilize in the long run as macroeconomic issues improve over our 10-year forecast period. We maintain our fair value estimate of $260 per share, and shares are currently trading in 4-star territory, presenting an attractive opportunity for long-term investors.